Inhalable carrier for heart gene delivery as well as preparation method and application of inhalable carrier

By using biomineralized calcium phosphate nanoparticles and liposome wrapping technology in the heart gene delivery system, efficient enrichment of gene therapy agents in the heart through inhalation administration is achieved, and the therapeutic agents caused by high blood flow in the heart are solved Difficulty in enrichment problems and provides a safe and efficient administration method suitable for chronic heart disease.

CN118976124APending Publication Date: 2024-11-19SHANGHAI SIXTH PEOPLES HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411100205.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The existing cardiac gene delivery system is difficult to effectively enrich therapeutic agents in the face of high cardiac blood flow, resulting in poor treatment results. Traditional administration methods such as intravenous and subcutaneous injections have complex operation, inaccurate positioning and Problems with obvious side effects are difficult to be suitable for long-term treatment of chronic heart disease.

Method used

The biomineralization strategy is used to synthesize calcium phosphate nanoparticles with high biocompatibility as gene vectors, and a targeted gene delivery system is constructed on their surface by liposomes. The genes carried by the vector are carried through the heart and lung circulation by inhalation delivery method. Enriched in the heart.

Benefits of technology

The cardiac enrichment effect through inhalation administration is 3-5 times higher than that of intravenous administration, which significantly improves cardiac function and reduces fibrosis and cardiomyocyte cross-sectional area, providing a safe, accurate and efficient method of cardiac gene delivery. Suitable for long-term treatment of chronic heart disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976124A_ABST
    Figure CN118976124A_ABST
Patent Text Reader

Abstract

The invention discloses an inhalable carrier for heart gene delivery as well as a preparation method and application of the inhalable carrier. According to the invention, Ca < 2 + >, PO4 < 3-> and specific siRNA generate a gene delivery compound carried by calcium phosphate by using a biomineralization method, and the surface of CaP is further coated with liposome, so that the stability of the gene in the delivery process is improved. The gene delivery compound prepared by the invention has the characteristic of inhalability, and the activity of siRNA is not changed after atomization; the gene delivery compound loaded with the siNOX4 can be enriched at the myocardial part after inhalation administration, can significantly improve myocardial hypertrophy, reduce fibrosis and improve cardiac contraction and diastole functions, and has a significant heart protection effect. The gene delivery system provided by the invention can replace an invasive drug delivery mode of traditional cardiac drug delivery, overcomes the problem of insufficient enrichment caused by cardiac hyperblood flow to a certain extent, and has a good application prospect in the aspect of cardiac gene therapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to an inhalable carrier for cardiac gene delivery and a preparation method and application thereof, belonging to the technical field of biomedicine. Background Art

[0002] Cardiovascular disease occurs in the heart and blood vessels and is the second leading cause of death worldwide. The main causes of cardiovascular disease include coronary artery disease, myocardial infarction and arrhythmia. Although some current treatments, including traditional small molecule therapy, gene therapy, cell reprogramming and stem cell transplantation, have been developed for heart regeneration after acute myocardial infarction, there is no effective cure for the disease. What is even more frightening is that some cardiovascular and cerebrovascular diseases will seriously affect the patient's ability to take care of themselves. Currently, more than 15 million people die from cardiovascular and cerebrovascular diseases each year worldwide, ranking first among all causes of death. It can be seen that the development of new therapies for the treatment of cardiovascular diseases is of great significance to human health.

[0003] In recent years, the rapid development of gene delivery vector technology and gene editing technology has promoted gene therapy to move steadily towards the clinic. As the second largest gene therapy clinical research subject after tumors, gene therapy for cardiovascular disease has shown great potential. The scientific research community has invested more energy and also attracted the attention of capital. In addition, another difficulty in cardiac gene therapy is that compared with other diseases, the special high-speed blood flow in the heart will lead to insufficient retention of the delivery system, which makes the existing treatment methods ineffective, especially when directly delivering functional repair molecules (such as proteins or RNA molecules) into cells. Therefore, how to overcome the high blood flow in the heart and increase the accumulation of therapeutic genes in the heart disease lesions is the key to achieving effective treatment.

[0004] Some advanced delivery systems that have been reported to induce cardioprotective or repair molecular mechanisms include miRNA therapy via antisense strategies, as well as adeno-associated virus (AAV) and lipid nanoparticle (LNP) delivery. AAVs, small virus-based vectors, are favored for their low pathogenicity and sustained gene expression. However, they face challenges such as immune response, high production costs, and limited genetic material capacity. In addition, AAVs can stimulate the immune system to produce neutralizing antibodies, which can affect the therapeutic effect and limit their use for repeated administration. This is particularly problematic for chronic diseases, where continuous treatment is required. Antisense strategies or lipid-based LNP approaches, which encapsulate genetic material in lipids as synthetic carriers, have significant issues in terms of toxicity and off-target effects. Safety concerns have been raised in serious adverse events, including one death in a CRISPR gene editor delivery trial, possibly due to the high doses required. Although careful dosing and the use of specific AAV serotypes can provide tissue selectivity and help improve off-target effects, other safer, more precise, and more effective delivery vectors are urgently needed in cardiovascular therapy to pave the way for further development in this field in the future.

[0005] On the other hand, the current methods of gene delivery targeting the heart include myocardial fixed-point injection, intravenous injection, coronary artery injection, subcutaneous injection, etc., among which myocardial fixed-point injection and tail vein injection are the main ones. Intravenous injection, subcutaneous injection or intramuscular injection are invasive, and have disadvantages such as complex operation, inaccurate positioning, and obvious side effects. They are also prone to cause patient discomfort and poor compliance, making these drug delivery methods unsuitable for long-term treatment of chronic heart disease. Therefore, developing a delivery strategy that can achieve good drug enrichment in the heart through non-invasive drug delivery is a challenge that needs to be urgently addressed in the current gene therapy of cardiovascular diseases. Summary of the invention

[0006] The purpose of the present invention is to address the many shortcomings of current cardiac drug delivery systems and drug administration methods and the technical problems of large side effects. The present invention provides an inhalable carrier for cardiac gene delivery and a preparation method and application thereof. The present invention synthesizes calcium phosphate nanoparticles (CaP) with high biocompatibility as gene carriers through a biomineralization strategy; in order to improve the stability of genes during delivery, a targeted gene delivery system is constructed by encapsulating liposomes on the surface of CaP.

[0007] In order to achieve the above object, the present invention adopts the following technical solutions:

[0008] The first aspect of the present invention provides a gene delivery system, comprising a delivery vector and an active pharmaceutical ingredient, wherein the delivery vector is a delivery vector formed by in situ encapsulation of liposomes on the surface of calcium phosphate, and the active pharmaceutical ingredient is a nucleic acid drug, which is a combination of any one or more of siRNA, mRNA, lncRNA, RNA aptamer and DNA.

[0009] Nucleic acid drugs can be divided into two categories: DNA and RNA. DNA is mainly used in fields such as gene editing and gene therapy, while RNA is divided into many types, including siRNA (small interfering RNA), miRNA (microRNA), IncRNA (long non-coding RNA), etc.

[0010] siRNA is mainly used to interfere with the expression of target genes, thereby achieving the treatment of diseases related to the corresponding target genes. miRNA mainly acts on physiological processes such as regulating gene expression, cell proliferation and differentiation. By regulating these cell physiological functions, the purpose of treating related diseases can be achieved; miRNA drugs can help downregulate the miRNA molecules of disease-related gene activity and downregulate the functions of some over-expressed disease-related miRNA molecules. There are two ways of miRNA drug treatment: one is to supplement miRNA with disease-suppressing function by using miRNA mimics, and the other is to inhibit miRNA that promotes disease occurrence by using miRNA inhibitors. lncRNA is a new type of RNA molecule that can regulate gene expression and protein synthesis by interacting with DNA, RNA or protein, and has broad theoretical research and application prospects. RNA aptamers are single-stranded RNAs (ssRNA) with unique three-dimensional conformations that enable them to specifically bind to target molecules. Aptamers can be relatively easily screened, reproducibly manufactured, programmably designed and chemically modified for various biomedical applications, including targeted therapy.

[0011] Preferably, the main components of the liposome are DOPA, lipids, cholesterol and DSPE-PEG; the lipids are selected from any one or more combinations of 1,2-didocosyl-sn-glycerol-3-phosphocholine (DBPC), 1,2-dipalmitoyl-sn-glycerol-3-phosphocholine (DPPC), 1,2-docosyl-sn-glycerol-3-phosphocholine (DLPC), 1,2-arachidonylphosphatidylcholine (DAPC), 1,2-dipalmitoyl-sn-glycerol-3-phosphatidic acid sodium salt (DPPA) and dipalmitoylphosphatidylethanolamine (DPPE);

[0012] The raw materials for preparing the calcium phosphate include calcium chloride, sodium citrate and phosphate.

[0013] Preferably, the nucleic acid drug is any one or more combinations of siRNA, mRNA, lncRNA, RNA aptamer and DNA specifically targeting the heart, and the gene delivery system is a gene delivery system targeting the heart.

[0014] The second aspect of the present invention provides a method for preparing the above-mentioned gene delivery system, comprising the following steps:

[0015] Step 1: Dissolve calcium chloride and sodium citrate in water to prepare a mixed solution, add the nucleic acid drug, and mix thoroughly to obtain solution A;

[0016] Step 2: dissolving phosphate in water to obtain solution B, mixing solution A and solution B, and adjusting the pH to alkaline with alkaline solution to carry out reaction; after the reaction is completed, centrifuging, collecting and washing the solid precipitate to obtain a calcium phosphate gene complex;

[0017] Step 3: Disperse the calcium phosphate gene complex prepared above in ethanol, add a chloroform solution of dioleoylphosphatidic acid sodium salt (DOPA), and mix well; then, purify by centrifugation to obtain DOPA-modified CaP nanoparticles;

[0018] Step 4: Re-disperse the above-mentioned DOPA-modified CaP nanoparticles in chloroform, and mix them with lipids, cholesterol and DSPE-PEG; remove the chloroform after stirring the reaction, hydrate the lipid film with phosphate buffer (PBS, pH = 7.4), and finally, purify by centrifugation to obtain the liposome-encapsulated calcium phosphate gene complex, which is the gene delivery system.

[0019] Preferably, the phosphate in step 2 is selected from any one or more combinations of Na2HPO4, NaH2PO4, K2HPO4 and KH2PO4.

[0020] Preferably, after solution A and solution B are mixed in step 2, the concentration ratio of calcium chloride, sodium citrate and phosphate in the system is 5-15:20-80:10-30; the mass molar ratio of the nucleic acid drug and calcium chloride is 25-250 μg:5-15 μmol, preferably 37-125 μg:5-15 μmol.

[0021] Preferably, after the solution A and the solution B are mixed, the concentration of calcium chloride in the system is 50-150 mM, the concentration of sodium citrate is 200-800 mM, and the concentration of phosphate is 100-300 mM; the concentration of the nucleic acid drug is 25-250 μg / mL, preferably 37-125 μg / mL.

[0022] Preferably, the alkali solution in step 2 is NaOH solution.

[0023] Preferably, in step 2, the pH is adjusted to 9-11.

[0024] Preferably, the components of the liposome in step 4 include DOPA, lipids, cholesterol and DSPE-PEG, and the molar ratio of the feeds is 0.5-1.5:1-2.5:0.6-0.9:0.15-0.45.

[0025] Preferably, the molecular weight of the DSPE-PEG is 2000-10000.

[0026] The third aspect of the present invention provides the use of the above-mentioned gene delivery system in the preparation of a drug for treating cardiovascular diseases, wherein the nucleic acid drug in the gene delivery system is any one or more combinations of siRNA, mRNA, lncRNA, RNA aptamer and DNA that specifically targets cardiovascular disease-related genes.

[0027] Preferably, the dosage form of the drug is an inhalation preparation, and the administration method is inhalation administration.

[0028] In the present invention, the cardiovascular diseases include but are not limited to myocardial hypertrophy, heart failure, myocardial infarction and myocarditis; the nucleic acid drugs include but are not limited to cardiac-specific NADPH oxidase 4 (NOX4) siRNA (siNOX4), apolipoprotein C3 (ApoC3) siRNA (siApoC3), growth differentiation factor 15 (GDF15) siRNA (siGDF15), miRNA-30d, miRNA-21, and miRNA-125a-5p.

[0029] In view of the many shortcomings and side effects of the current cardiac drug delivery system and administration method, and considering the advantages of inhalation administration, such as simple operation, good compliance, and relatively few systemic adverse reactions, the present invention synthesizes calcium phosphate nanoparticles (CaP) with high biocompatibility as gene carriers through a biomineralization strategy. In order to improve the stability of the gene during delivery, a targeted gene delivery system is constructed by encapsulating the surface of CaP with liposomes. After inhalation administration, the liposome-encapsulated calcium phosphate carrier can carry the loaded gene and enrich it in the heart through the cardiopulmonary circulation. The experimental results show that the inhalation administration method can be 3-5 times higher than intravenous administration in terms of cardiac enrichment effect, and it is expected to maximize the mitigation effect of RNA, DNA, etc. on cardiac fibrosis and cardiac remodeling, thereby achieving a good therapeutic effect. At the same time, as a representative verification, the present invention further explores the possibility of improving cardiac function and treating myocardial hypertrophy by constructing a mouse myocardial hypertrophy model through the delivery of cardiac-specific NADPH oxidase 4 (NOX4) siRNA (siNOX4). The results of animal experiments show that the gene delivery system loaded with siNOX4 in mice by inhalation administration can significantly improve cardiac function and reduce fibrosis and myocardial cell cross-sectional area. The present invention provides an inspiring non-viral cardiac nucleic acid delivery method and a delivery tool with transformational potential for the treatment of heart diseases.

[0030] Compared with the prior art, the present invention has the following beneficial effects:

[0031] 1) The present invention provides a delivery vector specifically targeting the heart: small interfering RNA (siRNA) therapy is considered to be a powerful therapeutic strategy for treating heart disease; however, finding a safe and effective siRNA delivery route in vivo is a major challenge in broadening its clinical application; due to the development of lipid nanoparticles (LNPs) as delivery vectors, many advances have been made in disease treatment; however, RNA therapy is still limited by safe, accurate and efficient delivery outside the liver; therefore, in order to fully realize the potential of genetic medicine, tools or technologies for cardiac targeted delivery of siRNA are urgently needed; the present invention designs a liposome-encapsulated calcium phosphate gene delivery vector, and forms an inhalable preparation through structural optimization, which greatly reduces the nonspecific uptake of the liver and achieves effective enrichment of the heart;

[0032] 2) The present invention solves the problem of cardiac delivery: the special high-speed blood flow in the heart makes it difficult for the drug delivery system to effectively enrich the lesion, making the existing delivery system ineffective in treating heart-related diseases; in addition, the current drug delivery methods for treating heart diseases mainly include oral or injection (intravenous or intramyocardial); however, during acute or chronic gastrointestinal congestion, intestinal absorption is often unreliable, and intravenous, subcutaneous or intramuscular injections are invasive, with the disadvantages of complex operation, inaccurate positioning, and obvious side effects, which can easily lead to patient discomfort and poor compliance, making these drug delivery methods unsuitable for long-term treatment of chronic heart disease; the gene delivery system of the present invention adopts an inhalation administration method, which is a gene delivery strategy that enhances cardiac enrichment. The preparation is effectively delivered and enriched to the heart through an inhalation device to exert its effect, solving the current problems of insufficient enrichment of cardiovascular disease drug delivery and invasive administration methods. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 . Schematic diagram of the preparation process of liposome-encapsulated calcium phosphate gene complexes for cardiac gene delivery.

[0034] Figure 2 .TEM images of (a) CaP and (b) CaP-siNOX4; (c) hydrodynamic diameters and (d) corresponding PDI values ​​of CaP and CaP-siNOX4.

[0035] Figure 3 .(a) TEM image and (b) hydrodynamic diameter of lipo@CaP-siNOX4 nanoparticles; (c) Zeta potential of CaP-siNOX4 and lipo@CaP-siNOX4; (d) Actual image of CaP-siNOX4 and lipo@CaP-siNOX4 dispersions after standing for seven days.

[0036] Figure 4 .(a) Changes in the hydrodynamic diameter of CaP-siNOX4 and (b) lipo@CaP-siNOX4 dispersions after incubation for a certain period of time; (c) homemade nebulization inhalation device for small animals; (d) hydrodynamic diameter distribution and PDI value of lipo@CaP-siNOX4 before and after nebulization.

[0037] Figure 5.(a) Cell survival rate detection after incubation of HUVECs, NIH / 3T3 and AC16 cells with different concentrations of lipo@CaP for 24 hours; (b) Red blood cell hemolysis percentage of lipo@CaP-siNOX4 nanoparticles with different concentrations in fresh blood and photos of the mixture after centrifugation, which are used to observe the hemoglobin content in the supernatant; (c) H&E staining images of major tissues of mice after inhalation administration of high concentrations of lipo@CaP or lipo@CaP-siNOX4.

[0038] Figure 6 .(a) GFP protein expression in HEK 293T cells after incubation with different concentrations of lipo@CaP-EGFP and (b) corresponding intracellular GFP flow cytometry results.

[0039] Figure 7 .(a) Representative images of cells after NRVMs were incubated with Cy5.5-labeled lipo@CaP-siNOX4 for different times; scale bar, 50 μm; (b) Semi-quantitative results of intracellular Cy5.5; (c) WB results of NOX4 expression in cells after NRVMs were incubated with different concentrations of lipo@CaP-siNOX4 and (d) semi-quantitative results of relative protein content.

[0040] Figure 8 (a) Cy5.5-labeled lipo@CaP-siNOX4 was used for in vitro imaging of heart and lung tissues after different administration methods to evaluate the enrichment of the delivery complex in the heart and lungs at different time points; semi-quantitative results of fluorescence signals of isolated heart (b) and lung tissues (c) 1 hour after administration; (d) Ca in different tissues 1 hour after different administration methods 2+ content.

[0041] Fig. 9 .(a) Photographs of isolated hearts of mice with myocardial hypertrophy model after different treatments (scale bar: 1 cm); (b) ratio of heart weight to body weight (HW / BW); (c) H&E staining (scale bar: 2 mm) of heart tissues in different treatment groups; (d) representative images of Masson staining (scale bar: 200 μm) and (e) Sirius red staining (scale bar: 200 μm); (f) qRT-PCR detection and analysis of NOX4 levels in heart tissues of different treatment groups.

[0042] Fig.10.Evaluation of cardiac function in myocardial hypertrophy model mice after different treatments: (a) representative echocardiograms after different treatments; (b) ejection fraction % (LVEF%); (c) fractional shortening % (LVFS%); (d) left ventricular end-systolic diameter (LVESD) and (e) left ventricular end-diastolic diameter (LVEDD); (f) peak shortening (PS), (g) maximum contraction rate (±dL / dt), (h) time to reach maximum contraction (TPS) and (i) time to reach 90% relaxation (TR90) measured after adult cardiomyocytes were isolated from mice in different treatment groups. DETAILED DESCRIPTION

[0043] In order to make the present invention more clearly understood, preferred embodiments are described in detail below with reference to the accompanying drawings.

[0044] The present invention relates to an inhalable liposome-encapsulated calcium phosphate and a gene delivery system mediated by the liposome, and a preparation method and application thereof. The liposome-encapsulated calcium phosphate is formed by in situ encapsulation of liposomes on the surface of calcium phosphate, and can be used as a carrier with good biocompatibility and meeting atomization requirements for nucleic acid encapsulation and transfection; the present invention utilizes a biomineralization method to encapsulate Ca 2 + PO4 3- Gene delivery complexes carried by calcium phosphate are generated with specific siRNA. At the same time, liposomes of a certain thickness are formed on the surface in a gentle manner, and the prepared gene delivery complex has the characteristics of being inhalable, and the activity of siRNA is not changed after atomization; the gene delivery complex loaded with siNOX4 can be enriched in the myocardial area after inhalation administration, which can effectively improve myocardial hypertrophy in mice, reduce fibrosis and improve cardiac contraction and relaxation function, and has a significant cardioprotective effect. The present invention provides a new carrier tool for efficient and accurate gene delivery to the heart, which is of great significance and potential application value for basic research and gene therapy of cardiovascular diseases.

[0045] Unless otherwise specified, the experimental methods in the examples of the present invention without specifying specific conditions shall be selected according to conventional methods and conditions, or according to the product instructions; the raw materials, reagents, etc. used in the examples of the present invention are conventional raw materials and reagents in the field and are commercially available unless otherwise specified, animal experiments comply with the ethical requirements for experimental animals, and the acquisition and testing of human tissue samples comply with medical ethical requirements.

[0046] Example

[0047] Preparation of an inhalable carrier for cardiac gene delivery (preparation process as described in Figure 1 As shown) and its application in a myocardial hypertrophy model, comprising the following steps:

[0048] 1. Preparation of Liposome-encapsulated Calcium Phosphate Gene Complex

[0049] (1) Preparation of calcium phosphate gene complex

[0050] Anhydrous calcium chloride and sodium citrate were dissolved in ultrapure water to prepare a mixed solution. A certain concentration of nucleic acid drug was added to the mixed solution with a sterile pipette. After thorough mixing, the solution was allowed to stand at room temperature for a certain period of time to obtain solution A. A certain amount of phosphate was dissolved in ultrapure water to obtain solution B. Equal volumes of solution A and B were mixed at room temperature, and the pH of the system was adjusted to about 10.0 using NaOH solution (0.1M) for 0.5-2h. After centrifugation, the product was washed with deionized water and ethanol to obtain a calcium phosphate gene complex. The nucleic acid drug is any one or more of siRNA, mRNA, lncRNA, RNA aptamer and DNA; the concentration of the nucleic acid drug in solution A is 50-500 μg / mL, preferably 75-250 μg / mL; the phosphate in solution B is any one or more of Na2HPO4, NaH2PO4, K2HPO4, KH2PO4; the concentrations of calcium chloride, sodium citrate and phosphate are 50-150 mM, 200-800 mM and 100-300 mM respectively. The synthesized calcium phosphate gene complex is characterized by transmission electron microscopy (TEM) and hydrodynamic diameter determination.

[0051] like Figure 2 As shown in a and b, the calcium phosphate gene complex prepared by the above steps is spherical, with a particle size of 62±4.5nm and a hydrodynamic diameter of about 79.9±3.2nm ( Figure 2 c), PDI is less than 0.2( Figure 2 d), indicating good dispersibility. At the same time, the loading of siRNA does not significantly affect the morphology and size of the calcium phosphate carrier.

[0052] (2) Preparation of lipo@CaP-siNOX4

[0053] The CaP gene complex prepared above (taking siNOX4 loaded (sequence: 5′-GCUUCUACCUAUGCAAUAATT-3′, SEQ ID NO: 1) as an example, denoted as CaP-siNOX4) was dispersed in ethanol, a certain amount of dioleoylphosphatidic acid sodium salt (DOPA) chloroform solution was added, and ultrasonic treatment was performed for 30 minutes to ensure uniform mixing. Then, the DOPA-modified CaP nanoparticles were purified by centrifugation and redispersed in chloroform, and then mixed with lipids, cholesterol and DSPE-PEG (distearoylphosphatidylethanolamine-polyethylene glycol) in a certain molar ratio. After vigorous stirring, the chloroform was completely removed using a rotary evaporator. The lipid film was hydrated with phosphate buffered saline (PBS, pH=7.4), and finally, the liposome-encapsulated calcium phosphate gene complex (denoted as lipo@CaP-siNOX4) was purified by centrifugation. The lipid is selected from any one or more of 1,2-didocosayl-sn-glycerol-3-phosphocholine (DBPC), 1,2-dipalmitoyl-sn-glycerol-3-phosphocholine (DPPC), 1,2-didocosayl-sn-glycerol-3-phosphocholine (DLPC), 1,2-arachidonylphosphatidylcholine (DAPC), 1,2-dipalmitoyl-sn-glycerol-3-phosphatidic acid sodium salt (DPPA), and dipalmitoylphosphatidylethanolamine (DPPE). The molecular weight of the DSPE-PEG is 2000-10000. In this embodiment, the liposome components include DOPA, lipids, cholesterol, and DSPE-PEG. More specifically, the molar ratio of the feed is 0.5-1.5: 1-2.5: 0.6-0.9: 0.15-0.45. The synthesized liposome-encapsulated calcium phosphate gene complex was characterized by transmission electron microscopy (TEM), hydrodynamic diameter, and surface potential measurement.

[0054] From the TEM image, it can be seen that the prepared lipo@CaP-siNOX4 nanoparticles have a uniform spherical topological structure and a transparent organic surface (liposome). The thickness of the liposome is about 12nm, and the overall average particle size is larger than that of CaP-siNOX4, about 87±3.7nm ( Figure 3 a). Similarly, its hydrodynamic diameter is 106±5.4nm ( Figure 3 b). We found through surface charge testing that when CaP-siNOX4 was encapsulated in liposomes, its surface potential changed from -26.8±3.2mV to 13.7±2.3mV ( Figure 3 c), proving the successful encapsulation of CaP-siNOX4 surface liposomes. Figure 3d) It can be seen that the prepared lipo@CaP-siNOX4 forms a white suspension in PBS and can be well dispersed in different dispersion media, which is suitable for subsequent biological applications.

[0055] 2. Investigation of the physicochemical and atomization properties of lipo@CaP-siNOX4

[0056] CaP-siNOX4 and lipo@CaP-siNOX4 were prepared as described in step 1. The particle size change of the dispersion within 1 week was measured by laser particle size analyzer to investigate the stability of the delivery system.

[0057] like Figure 4 As shown in a, the particle size of CaP-siNOX4 increases with the extension of incubation time, which is due to the aggregation and even sedimentation of CaP nanoparticles. After 48h of incubation, the particle size is too large to be measured. In contrast, the particle size of lipo@CaP-siNOX4 nanoparticles can remain stable within 7 days ( Figure 4 b) It can also be seen from the actual picture that CaP-siNOX4 showed obvious aggregation after being placed for 12 hours, while lipo@CaP-siNOX4 was still well dispersed in the solution. This shows that the stability of CaP nanoparticles loaded with siNOX4 is greatly improved after being encapsulated by liposomes.

[0058] The particle size and aggregation index (PDI) of lipo@CaP-siNOX4 before and after atomization were measured by laser particle size analyzer. The atomization device consists of a six-channel receiving tube with air circulation holes and an airtight tube for the nebulizer (such as Figure 4 c). During aerosol administration, the lipo@CaP-siNOX4 suspension was added to the nebulizer, which was connected to an airtight tube. The sprayed droplets could be delivered to the receiving tube and inhaled by the mice. In vitro results showed that after aerosolization of lipo@CaP-siNOX4, the particle size and PDI did not change significantly ( Figure 4 d), indicating that its structure can maintain integrity after atomization.

[0059] 3. Biosafety evaluation of lipo@CaP-siNOX4 delivery system

[0060] (1) Evaluation of lipo@CaP carrier cell compatibility

[0061] Human umbilical vein endothelial cells (HUVECs), mouse embryonic fibroblasts (NIH / 3T3) and human cardiomyocytes (AC16) were cultured at a density of 5×10 3Cells / well were inoculated into 96-well plates containing 100 μL DMEM medium and cultured for 24 hours. After the cells were completely attached, the medium was removed, and lipo@CaP in a certain concentration range (0-500 μg / mL) was co-incubated with different cells for 24 hours, the cell state was observed, and the cytotoxicity was detected by CCK-8 method.

[0062] Experimental results: CCK-8 test results are as follows Figure 5 As shown in a, even when incubated with a high concentration of 500 μg / mL lipo@CaP, the survival rate of the three cells was only less than 80% for HUVECs after 24 h of incubation, indicating that lipo@CaP has good cell compatibility.

[0063] (2) Hemolysis rate test

[0064] Normal rat blood was mixed with physiological saline, different concentrations of lipo@CaP-siNOX4 or deionized water, and incubated at 37°C for 1 hour. The mixed solution was then centrifuged, and the supernatant was collected and the absorbance value at a wavelength of 405 nm was detected by an ELISA instrument.

[0065] The results of the hemolysis experiment showed that the hemolysis rates of lipo@CaP-siNOX4 nanoparticles at different concentrations were less than 5% compared with deionized water ( Figure 5 b) Meet the requirements of material safety.

[0066] (3) Histocompatibility testing

[0067] All animal experiments were performed in accordance with the guidelines of the Experimental Animal Care and Use Committee of the Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. Balb / c mice were purchased from Nanjing Pengsheng Biotechnology Co., Ltd. First, lipo@CaP-siNOX4 in PBS solution (1.5 mg / mL) was administered to normal mice by inhalation, and different tissues were taken for pathological sections after injection to verify the biosafety of the transfection reagent.

[0068] like Figure 5 As shown in c, after inhalation administration of high-concentration lipo@CaP or lipo@CaP-siNOX4 PBS solution, different tissues (heart, liver, spleen, lung, and kidney) were taken for H&E staining, and no obvious apoptotic or necrotic cells were observed in various organs, demonstrating that the prepared gene-carrying complex has good biosafety and is suitable for subsequent in vivo experiments.

[0069] 4. Gene transfection test at the cellular level

[0070] (1) Detection of gene transfection by fluorescence microscopy and flow cytometry

[0071] Enhanced green fluorescent protein (EGFP) gene transfection was used to verify the transfection efficiency of the delivery system. First, lipo@CaP-EGFP was prepared as described in step 1. HEK 293T cells were cultured at 1.2×10 5 The cells were seeded at a density of 10 cells / well in 1.6 mL of RPMI 1640 medium containing 10% FBS and incubated for 48 hours to ensure cell adhesion. Afterwards, the culture medium was replaced with the prepared lipo@CaP-EGFP solution (50 μg / mL), ensuring that the total volume remained unchanged at 1.6 mL. After incubation for different hours, the culture medium of each well was removed, and fresh culture medium was added to continue incubation, keeping the total incubation time at 48 hours. The cells were then observed under a fluorescence microscope. In addition, the cell transfection experiment was carried out according to the above process. After transfection, the cells were digested with trypsin, the supernatant was discarded after centrifugation for 5 minutes, and the cells were resuspended in 0.5 mL PBS (pH 7.4), and then the expression of green fluorescent protein in different groups of samples was analyzed by flow cytometry.

[0072] Experimental results: Figure 6 As shown in a, the GFP protein expression level (fluorescence brightness) in the lipo@CaP group carrying the plasmid DNA containing the GFP reporter gene increased with the increase of the lipo@CaP-EGFP concentration, proving that the prepared lipo@CaP can be used as a universal gene delivery vector. In addition, lipo@CaP has a stronger gene transfection efficiency and average fluorescence intensity than CaP alone. At the same time, the results of the expression of the encoded protein determined by fluorescence microscopy are consistent with the results of flow cytometry determination ( Figure 6 b).

[0073] (2) Detection of targeted delivery performance of lipo@CaP-siNOX4 in cardiomyocytes

[0074] By culturing isolated cardiomyocytes (NRVMs) in vitro, isoproterenol (PE) was added to the cells to stimulate the cells to cause cell hypertrophy. After lipo@CaP-siNOX4 was labeled with Cy5.5 fluorescent probe and incubated with NRVMs cells for 24 hours, the cells were washed three times with PBS, fixed with 4% paraformaldehyde, and the nuclei were stained with DAPI, and then observed using a confocal microscope. The cells were then treated with lipo@CaP-siNOX4 for 4 hours. Subsequently, the cell samples were subjected to Western blot analysis to detect the expression of NOX4 in the cells. Among them, the primary antibodies NOX4 (ab133303, 1:500) and β-actin (sc-47778, 1:1000) were purchased from Abcam (Cambridge, UK).

[0075] The results showed that lipo@CaP-siNOX4 could be well taken up by NRVMs cells stimulated by PE, and judging from the Cy5.5 fluorescence in the figure, the uptake behavior had a clear time dependence ( Figure 7 a, b). In addition, by analyzing the expression of NOX4 in the cells of NRVMs treated with different concentrations of lipo@CaP-siNOX4, it can be seen that with the increase of concentration, the expression of NOX4 gradually decreased. When the concentration reached 100 μg / mL, the expression of NOX4 in the cells was very low ( Figure 7 bd). These results indicate that lipo@CaP-siNOX4 has good targeted gene delivery performance to cardiomyocytes in vitro.

[0076] 5. Investigation of cardiac accumulation and biodistribution of inhaled lipo@CaP-siNOX4

[0077] All animal experiments were performed in accordance with protocols approved by the Animal Care and Utilization Committee of the Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. First, lipo@CaP-siNOX4 was labeled with a fluorescent dye (Cy5.5). Normal mice were randomly divided into groups to investigate the cardiac enrichment effect of lipo@CaP-siNOX4 after administration by different administration methods (intravenous injection, intraperitoneal injection, and inhalation). A certain dose of Cy5.5-lipo@CaP-siNOX4 in normal saline was administered to mice by different administration methods. For the inhalation administration group, mice received intratracheal treatment through an inhalation device. At different times after administration, in vivo fluorescence imaging was used to detect the enrichment of nanoparticles in the heart. At the same time, different tissues were taken out at the time point with the strongest in vivo fluorescence for inductively coupled plasma optical emission spectrometry (ICP-OES) analysis of the biodistribution (in terms of Ca) of the labeled nanoparticles in normal organs (heart, liver, spleen, lung, kidney and brain, etc.). 2+ as the detection object).

[0078] Experimental results: Compared with intravenous injection and intraperitoneal administration, inhalation administration can lead to better cardiac enrichment of lipo@CaP-siNOX4 nanoparticles ( Figure 8 a). In addition, over time, the accumulation of lipo@CaP-siNOX4 in the myocardium (increased Cy5.5 fluorescence) was accompanied by an attenuation signal in the lungs, indicating that it had passed through the lung barrier. Semi-quantitative analysis of fluorescence showed that at the peak time point (1 h), the myocardial accumulation of lipo@CaP-siNOX4 by inhalation was significantly greater than that of the other two administration methods ( Figure 8 b). Next, we took out different tissues for ICP-OES quantitative detection at the time point when the heart fluorescence was strongest ( Figure 8c) The results further confirmed that inhaled lipo@CaP-siNOX4 has a good cardiac enrichment effect, and its content in normal tissues is also lower than that of intravenous or intraperitoneal administration. Therefore, the inhalation preparation of the present invention can reduce the nonspecific distribution during siRNA delivery and improve the delivery efficiency.

[0079] 6. Evaluation of the anti-cardiac hypertrophy effect of inhaled lipo@CaP-siNOX4 in vivo

[0080] C57BL / 6 male mice were selected to establish a myocardial hypertrophy model. The mice were injected intraperitoneally with tiltamine-zolazepam and xylazine ( 10mg / kg) and implanted with angiotensin II (Ang II) 1002 micro-osmotic pump (1.5 mg / kg / day). After 7 days, the model mice were administered lipo@CaP or lipo@CaP-siNOX4 by inhalation. After the treatment, the heart tissues of each group were weighed to calculate the heart weight to bodyweight (HW / BW). Subsequently, the heart tissues of each treatment group were stained with H&E, Masson and Sirius Red to evaluate the therapeutic effect. At the same time, we performed qRT-PCR detection on the heart tissues of each treatment group to analyze the effect of lipo@CaP-siNOX on NOX4 at the in vivo level.

[0081] Experimental results: Compared with the sham operation group, the heart size of the PBS group and lipo@CaP treatment group ( Fig. 9 a) and heart weight / body weight ratio ( Fig. 9 b) significantly increased. The above pathological conditions were significantly improved by inhalation of lipo@CaP-siNOX4. Pathological analysis of the samples after treatment revealed that H&E ( Fig. 9 c), Masson staining ( Fig. 9 d) and Sirius staining ( Fig. 9 e) shows that there is extensive cardiac fibrosis in mice treated with PBS and lipo@CaP. In contrast, the degree of fibrosis in mice treated with lipo@CaP-siNOX4 inhalation was significantly improved. By measuring the level of NOX4 in cardiac tissue, it was found that the NOX4 level in the heart tissue of mice was significantly reduced after lipo@CaP-siNOX4 inhalation treatment, proving that lipo@CaP successfully delivered siNOX4 to the mouse heart ( Fig. 9 f). The results showed that lipo@CaP-siNOX4 inhalation therapy could effectively alleviate the pathological process of myocardial hypertrophy in the mouse model.

[0082] 7. Effects of inhaled CaP-PEG-CP-PDEi on cardiac function in mouse models

[0083] Seven days after the model was established, mice were administered lipo@CaP or lipo@CaP-siNOX4 by inhalation. After one week of treatment, the mice in different treatment groups were examined by echocardiography every two days using a multimodal small animal ultrasound imaging system, and relevant parameters such as left ventricular ejection fraction (LVEF%), left ventricular shortening fraction (LVFS%), left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD) were obtained to evaluate the systolic and diastolic function of the heart.

[0084] Experimental results: The mice receiving different treatments ( Fig.10 a). As can be seen from the echocardiogram, both LVEF% and LVFS% can be significantly improved by inhaled lipo@CaP-siNOX4 treatment ( Fig.10 b, c). In addition, LVESD and LVEDD were significantly improved after inhaled lipo@CaP-siNOX4 treatment ( Fig.10 d, e), preliminarily indicating that inhaled lipo@CaP-siNOX4 can effectively improve the cardiac function of myocardial hypertrophy model mice. Next, the shortening / re-enhancement capacity was evaluated by isolating cardiomyocytes. Consistent with the results of echocardiography, the contractile function of mice treated with inhaled lipo@CaP-siNOX4 was significantly improved, as shown by an increase in parameters such as peak shortening (PS%), maximum contraction rate (±dL / dt), time to reach maximum contraction (TPS), and time to reach 90% relaxation (TR90) ( Fig.10 fi), indicating that lipo@CaP-siNOX4 inhalation treatment effectively improved the cardiac systolic and diastolic function of TAC-induced heart failure mice and had a significant cardioprotective effect.

[0085] The above description is only a preferred embodiment of the present invention and is not any formal or substantial limitation of the present invention. It should be pointed out that a person skilled in the art can make several improvements and supplements without departing from the present invention, and these improvements and supplements should also be regarded as the protection scope of the present invention.

Claims

1. A gene delivery system, characterized in that The invention comprises a delivery carrier and an active pharmaceutical ingredient, wherein the delivery carrier is a delivery carrier formed by in situ encapsulation of liposomes on the surface of calcium phosphate, and the active pharmaceutical ingredient is a nucleic acid drug, which is any one or more combinations of siRNA, mRNA, lncRNA, RNA aptamer and DNA.

2. The gene delivery system according to claim 1, characterized in that The main components of the liposome are DOPA, lipids, cholesterol and DSPE-PEG; the lipids are selected from any one or more combinations of 1,2-didocayl-sn-glycerol-3-phosphocholine (DBPC), 1,2-dipalmitoyl-sn-glycerol-3-phosphocholine (DPPC), 1,2-docosyl-sn-glycerol-3-phosphocholine (DLPC), 1,2-arachidonylphosphatidylcholine (DAPC), 1,2-dipalmitoyl-sn-glycerol-3-phosphatidic acid sodium salt (DPPA) and dipalmitoylphosphatidylethanolamine (DPPE); The raw materials for preparing the calcium phosphate include calcium chloride, sodium citrate and phosphate.

3. The gene delivery system according to claim 1, characterized in that The nucleic acid drug is any one or more combinations of siRNA, mRNA, lncRNA, RNA aptamer and DNA specifically targeting the heart, and the gene delivery system is a gene delivery system targeting the heart.

4. The method for preparing a gene delivery system according to any one of claims 1 to 3, characterized in that: The following steps are involved: Step 1: Dissolve calcium chloride and sodium citrate in water to prepare a mixed solution, add the nucleic acid drug, and mix thoroughly to obtain solution A; Step 2: dissolving phosphate in water to obtain solution B, mixing solution A and solution B, and adjusting the pH to alkaline with alkaline solution to carry out reaction; after the reaction is completed, centrifuging, collecting and washing the solid precipitate to obtain a calcium phosphate gene complex; Step 3: Disperse the calcium phosphate gene complex prepared above in ethanol, add a chloroform solution of dioleoylphosphatidic acid sodium salt (DOPA), and mix well; then, purify by centrifugation to obtain DOPA-modified CaP nanoparticles; Step 4: Re-disperse the above-mentioned DOPA-modified CaP nanoparticles in chloroform, and mix them with lipids, cholesterol and DSPE-PEG; remove the chloroform after stirring the reaction, hydrate the lipid membrane with phosphate buffer, and finally, purify by centrifugation to obtain the liposome-encapsulated calcium phosphate gene complex, which is the gene delivery system.

5. The preparation method according to claim 4, characterized in that: The phosphate in step 2 is selected from any one or more combinations of Na2HPO4, NaH2PO4, K2HPO4 and KH2PO4.

6. The preparation method according to claim 4, characterized in that: After solution A and solution B are mixed in step 2, the concentration ratio of calcium chloride, sodium citrate and phosphate in the system is 5-15:20-80:10-30; the mass molar ratio of the nucleic acid drug and calcium chloride is 25-250 μg:5-15 μmol, preferably 37-125 μg:5-15 μmol. Preferably, after the solution A and the solution B are mixed, the concentration of calcium chloride in the system is 50-150 mM, the concentration of sodium citrate is 200-800 mM, and the concentration of phosphate is 100-300 mM; the concentration of the nucleic acid drug is 25-250 μg / mL, preferably 37-125 μg / mL.

7. The preparation method according to claim 4, characterized in that: The components of the liposome in step 4 include DOPA, lipids, cholesterol and DSPE-PEG, and the molar ratio of the feeds is 0.5-1.5:1-2.5:0.6-0.9:0.15-0.

45.

8. Use of the gene delivery system according to any one of claims 1 to 4 in the preparation of a drug for treating cardiovascular diseases, characterized in that: The nucleic acid drug in the gene delivery system is any one or more combinations of siRNA, mRNA, lncRNA, RNA aptamer and DNA that specifically targets cardiovascular disease-related genes.

9. The use according to claim 8, characterized in that: The dosage form of the medicine is an inhalation preparation, and the administration method is inhalation administration.

10. The use according to claim 8, characterized in that: The cardiovascular diseases include myocardial hypertrophy, myocardial enlargement, heart failure, myocardial infarction and myocarditis; the nucleic acid drugs include cardiac-specific NADPH oxidase 4 siRNA (siNOX4), apolipoprotein C3 siRNA (siApoC3), growth differentiation factor 15 siRNA (siGDF15), miRNA-30d, miRNA-21, and miRNA-125a-5p.